In conclusion, we have characterized a novel STRBP-JAK2 fusion gene for the first time in a refractory Ph-like ALL patient who failed to respond to conventional chemotherapy plus ruxolitinib. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.